Skip to main content
. 2011 Jun 15;6(6):e21018. doi: 10.1371/journal.pone.0021018

Figure 8. CDC.

Figure 8

PI staining followed by flow cytometry was used to analyze the CDC potency of IgG1 R11, R12, and Y31 in comparison to IgG1 P14 (negative control), and rituximab (RTX; positive control; all at 10 µg/mL) toward JeKo-1 cells (left), HBL-2 cells (middle), and PBMC from patient CLL-6 (right) in the presence of rabbit complement. The percentage of dead cells (PI-positive) after RTX-mediated CDC was 70.7% (JeKo-1), 54.4% (HBL-2), and 12.7% (CLL).